HONG KONG – The Chinese stock market has spent the first three weeks of the year in a virtual free fall, hitting a year-long bottom last Friday. Two weeks of constant drops have spooked overseas investors who have pulled their money out of the market. The good news for biopharma investors, however, is that the space has held up relatively well, and the overall pharma market in China is still expected to experience double-digit growth.